Corundum Group Inc. Sells 28,939 Shares of Pfizer Inc. (NYSE:PFE)

Corundum Group Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 67.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,802 shares of the biopharmaceutical company's stock after selling 28,939 shares during the period. Corundum Group Inc.'s holdings in Pfizer were worth $366,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Gladius Capital Management LP raised its position in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP purchased a new stake in Pfizer in the 2nd quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management increased its stake in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PFE. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target on the stock. StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Guggenheim lowered their target price on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $32.00.

Pfizer Stock Down 0.7 %

Shares of Pfizer stock traded down $0.19 on Monday, reaching $26.30. The company's stock had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. The company has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm's fifty day simple moving average is $26.08 and its two-hundred day simple moving average is $27.99.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) EPS. The business's revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's dividend payout ratio is presently 227.03%.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.